CelebrexThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

1070 records returned

[Inhibitory effects of COX-2 inhibitor on migration of human tongue squamous cell carcinoma Tca8113 cells.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: COX-2 inhibitor celecoxib can inhibit Tca8113 cell migration, the mechanism of which awaits further investigation. PMID: 19923064 [PubMed - as supplied by publisher] (Source: Journal of Southern Medical University)
Source: Journal of Southern Medical University - November 20, 2009 Category: Universities & Medical Training Authors: Huo QJ, Li WZ Tags: Nan Fang Yi Ke Da Xue Xue Bao Source Type: journals

Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) developed as a selective inhibitor of cyclooxygenase-2 (COX-2). Despite the associated cardiovascular toxicity risk, celecoxib has been found to be effective in reducing cancer risk in animal and human studies. In the present study the antiproliferative activity of novel nitro-oxy-methyl substituted analogues of celecoxib (NO-cel), potentially less cardiotoxic, has been investigated in vitro on human colon cancer cells and compared with action of the parent drug. Moreover, experiments were performed in order to evaluate whether COX-2 pharmacological inhibition...
Source: Chemico-Biological Interactions - November 18, 2009 Category: Molecular Biology Authors: Bozzo F, Bassignana A, Lazzarato L, Boschi D, Gasco A, Bocca C, Miglietta A Tags: Chem Biol Interact Source Type: journals

Pregabalin, celecoxib, and their combination for treatment of chronic low-back painEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions Combination of celecoxib and pregabalin is more effective than monotherapy for chronic low-back pain, with similar adverse effects. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s10195-009-0077-zAuthors Carlo Luca Romanò, Istituto Ortopedico I.R.C.C.S. Galeazzi Via Riccardo Galeazzi, 4 20166 Milan ItalyDelia Romanò, Istituto Ortopedico I.R.C.C.S. Galeazzi Via Riccardo Galeazzi, 4 20166 Milan ItalyCristina Bonora, Istituto Ortopedico I.R.C.C.S. Galeazzi Via Riccardo Galeazzi, 4 20166 Milan ItalyGiuseppe Mineo, Università degli Studi di Milano Istituto Ortopedico I.R.C.C...
Source: Journal of Orthopaedics and Traumatology - November 18, 2009 Category: Orthopaedics Tags: Journal of Orthopaedics and Traumatology Source Type: journals

Matrix Metalloproteinase (MMP)-1 and MMP-3 Induce Macrophage MMP-9: Evidence for the Role of TNF-{alpha} and Cyclooxygenase-2.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Matrix metalloproteinase (MMP)-9 (gelatinase B) participates in a variety of diverse physiologic and pathologic processes. We recently characterized a cyclooxygenase-2 (COX-2)-->PGE(2)-->EP4 receptor axis that regulates macrophage MMP-9 expression. In the present studies, we determined whether MMPs, commonly found in inflamed and neoplastic tissues, regulate this prostanoid-EP receptor axis leading to enhanced MMP-9 expression. Results demonstrate that exposure of murine peritoneal macrophages and RAW264.7 macrophages to MMP-1 (collagenase-1) or MMP-3 (stromelysin-1) lead to a marked increase in COX-2 expression,...
Source: Journal of Immunology - November 18, 2009 Category: Allergy & Immunology Authors: Steenport M, Khan KM, Du B, Barnhard SE, Dannenberg AJ, Falcone DJ Tags: J Immunol Source Type: journals

Celecoxib loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We describe here the encapsulation of CLX in multilamellar vesicles (MLVs) composed of DSPC and variable amounts of cholesterol. The effect of cholesterol content on liposome size, percent drug loading and in vitro drug release profiles were investigated. Differential scanning calorimetry and Fourier transform infrared (FTIR) spectroscopy were used to determine molecular interactions between CLX, cholesterol and DSPC. The phase transition temperature (Tm) of vesicles was reduced in a synergistic manner in the presence of both CLX and cholesterol. Encapsulation efficiency, loading and release of CLX decreased with increasin...
Source: Bioscience Reports - November 10, 2009 Category: Biomedical Science Authors: Deniz A, Sade A, Severcan F, Keskin D, Tezcaner A, Banerjee S Tags: Biosci Rep Source Type: journals

Biotransformation of Celecoxib Using Microbial Cultures.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Microbial transformation studies can be used as models to simulate mammalian drug metabolism. In the present investigation, biotransformation of celecoxib was studied in microbial cultures. Bacterial, fungal, and yeast cultures were employed in the present study to elucidate the metabolism of celecoxib. The results indicate that a number of microorganisms metabolized celecoxib to various levels to yield eight metabolites, which were identified by high-performance liquid chromatography diode array detection and liquid chromatography tandem mass spectrometry analyses. HPLC analysis of biotransformed products indicated th...
Source: Applied Biochemistry and Biotechnology - November 7, 2009 Category: Biochemistry Authors: Srisailam K, Veeresham C Tags: Appl Biochem Biotechnol Source Type: journals

The Effects of Nepafenac and Amfenac on Retinal Angiogenesis.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Nepafenac and amfenac inhibit OIR more effectively than the commercially available topical and injectable NSAIDs used in this study. Our data suggests there are COX-dependent and COX-independent mechanisms by which amfenac inhibits OIR. Because it is bioavailable to the posterior segment following topical delivery, nepafenac appears to be a promising advancement in the development of therapies for neovascular eye diseases. PMID: 19897019 [PubMed - as supplied by publisher] (Source: Brain Research Bulletin)
Source: Brain Research Bulletin - November 5, 2009 Category: Neurology Authors: Yanni SE, Clark ML, Yang R, Bingaman DP, Penn JS Tags: Brain Res Bull Source Type: journals

Pharmacological Inhibition of 5-Lipoxygenase Accelerates and Enhances Fracture-HealingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Systemic inhibition of 5-lipoxygenase with an orally delivered drug significantly accelerated and enhanced fracture-healing in this rat model. Gene expression analysis indicates that cyclooxygenase-2 is necessary for callus chondrocytes to progress into hypertrophy so as to complete endochondral ossification. Conversely, inhibition of 5-lipoxygenase alters the inflammatory response, which enhances callus chondrocyte hypertrophy and accelerates endochondral ossification. Clinical Relevance: These results suggest a novel approach to the treatment of human fractures and demonstrate that arachidonic acid metabolis...
Source: JBJS [Am] - November 2, 2009 Category: Orthopaedics Authors: Cottrell, J. A., O'Connor, J. P. Tags: Adult Trauma, Basic Science Scientific Articles Source Type: journals

A Novel Composite Endpoint to Evaluate the Gastrointestinal (GI) Effects of Nonsteroidal Antiinflammatory Drugs Through the Entire GI Tract.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: By providing clinicians with a new, descriptive language for adverse events through the entire GI tract, the CSULGIE endpoint has the potential to become a standard tool for evaluating the GI effects of a range of therapies. PMID: 19884267 [PubMed - as supplied by publisher] (Source: J Rheumatol)
Source: J Rheumatol - November 2, 2009 Category: Rheumatology Authors: Chan FK, Cryer B, Goldstein JL, Lanas A, Peura DA, Scheiman JM, Simon LS, Singh G, Stillman MJ, Wilcox CM, Berger MF, Breazna A, Dodge W Tags: J Rheumatol Source Type: journals

Pharmacological inhibition of 5-lipoxygenase accelerates and enhances fracture-healing.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Systemic inhibition of 5-lipoxygenase with an orally delivered drug significantly accelerated and enhanced fracture-healing in this rat model. Gene expression analysis indicates that cyclooxygenase-2 is necessary for callus chondrocytes to progress into hypertrophy so as to complete endochondral ossification. Conversely, inhibition of 5-lipoxygenase alters the inflammatory response, which enhances callus chondrocyte hypertrophy and accelerates endochondral ossification. PMID: 19884440 [PubMed - in process] (Source: The Journal of Bone and Joint Surgery. American volume)
Source: The Journal of Bone and Joint Surgery. American volume - November 1, 2009 Category: Orthopaedics Authors: Cottrell JA, O'Connor JP Tags: J Bone Joint Surg Am Source Type: journals

Effects of No.2 Renal Failure Recipe on expressions of cyclooxygenase-2 and -1 mRNAs in rats with chronic renal failure.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Objective: To observe the effects of No.2 Renal Failure Recipe (No.2RFR), a compound traditional Chinese herbal medicine, on expressions of cyclooxygenase-2 (COX-2) and cyclooxygenase-1 (COX-1) mRNAs in rats with chronic renal failure (CRF). Methods: A rat model of CRF was successfully established by infarction of approximately two-thirds of the left kidney and removal of the right kidney (ablation/infarction, A/I). Thirty A/I rats were randomly divided into untreated group, celebrex group and No.2RFR group. Another 10 SD rats were selected as normal control group. After 2-month treatment, the pathology of the nephridi...
Source: Zhong xi yi jie he xue bao : Journal of Chinese Integrative Medicine. - November 1, 2009 Category: Complementary Medicine Authors: Pu GJ, Wang C, Zheng PD, He LQ Tags: Zhong Xi Yi Jie He Xue Bao Source Type: journals

Is Short-Term Celecoxib Intervention A Effective Method For Preventing Gastric Carcinogenesis?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Since the isolation and culture of Helicobacter pylori (H. pylori) in 1983, this bacterium has become accepted as an important human pathogen for the development of gastritis, peptic ulcer, and gastric cancer. Cyclooxgenase-2 (COX-2) is a prostaglandin-synthesizing enzyme. Elevated expression of COX-2 is observed in a wide variety of human malignancies, including gastric cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 30, 2009 Category: Consumer Health News Tags: GastroIntestinal / Gastroenterology Source Type: news

The PI3K/Akt/FOXO3a/p27(Kip1) signaling contribuTES to Anti-inflammatory Drug-suppressed proliferation of human osteoblasts.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we hypothesized that these drugs might increase p27(Kip1) expression in hOBs by altering the Akt/FOXO signaling. We tested this hypothesis by examining the influences of three anti-inflammatory drugs on the levels and/or activities of Akt, FOXO and p27(Kip1) as well as the relationship between these factors and proliferation of hOBs. We tested the effects of indomethacin (10(-5) and 10(-4)M), celecoxib (10(-6) and 10(-5)M), and dexamethasone (10(-7) and 10(-6)M) using PI3K inhibitor, LY294002 (10(-5)M) as the basis of comparison. The three drugs suppressed the canonical level of phosphorylated Akt in hOBs. T...
Source: Biochemical Pharmacology - October 30, 2009 Category: Drugs & Pharmacology Authors: Li CJ, Chang JK, Chou CH, Wang GJ, Ho ML Tags: Biochem Pharmacol Source Type: journals

Bextra-Celebrex Judge Approves $89M Settlement Resolving Consumer ClaimsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN FRANCISCO - An $89 million settlement of consumer claims over Pfizer Inc.'s painkillers Bextra and Celebrex was approved Sept. 28 by the federal judge supervising consolidated litigation (In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, MDL Docket No. 1699, No. M:05-CV-1699, N.D. Calif.; See September 2009, Page 12). Full story on lexis.com (Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News)
Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News - October 29, 2009 Category: Medical Law Source Type: info

Bextra/Celebrex Objectors Claim Disparate Treatment In Consumer SettlementEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN FRANCISCO - Two objectors to a proposed $89 million class settlement of purchase price claims over Pfizer's painkillers Bextra and Celebrex filed a supplemental objection on Sept. 23, arguing that class members who purchased both drugs should be able to recover for purchases of Celebrex (In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, MDL Docket No. 1699, No. 05-1699, N.D. Calif.; See September 2009, Page 12). Full story on lexis.com (Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News)
Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News - October 29, 2009 Category: Medical Law Source Type: info

Judge Says Sealed Papers Were Not Relevant To Summary JudgmentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NEWARK, N.J. - The judge presiding over shareholder derivative litigation brought in New Jersey by labor union pension funds over Pfizer Inc.'s painkiller Celebrex has denied a plaintiffs' motion to unseal internal corporate communications, saying Oct. 20 that the documents were irrelevant to the only decision in the case - her grant of summary judgment on statute of limitations grounds (Robert L. Garber, et al. v. Pharmacia Corp., et al., No. 3:03-cv-01519, D. N.J.; See July 2009, Page 12). Full story on lexis.com (Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News)
Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News - October 29, 2009 Category: Medical Law Source Type: info

Is short-term Celecoxib intervention a effective method for preventing gastric carcinogenesis?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(World Journal of Gastroenterology) Helicobacter pylori has been accepted as an important pathogen inducing gastric cancer. A research group from Taiwan investigated optimal intervention point of Celecoxib, to inhibit H. pylori-associated gastric carcinogenesis in Mongolian gerbils. They found that short-term use resulted in less severe inflammation and inhibited the invasion degree of gastric cancer. Therefore, Celecoxib could be used in the later stages of H. pylori infection to achieve safe and effective chemoprevention of gastric adenocarcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 28, 2009 Category: Global & Universal Source Type: news

Effect of celecoxib on emotional stress and pain-related behaviors evoked by experimental tooth movement in the rat.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The administration of celecoxib relieves pain- and stress-related behavior evoked by orthodontic tooth movement in the rat. This model might be a useful tool for the evaluation of pain and stress. PMID: 19852611 [PubMed - in process] (Source: The Angle Orthodontist)
Source: The Angle Orthodontist - October 27, 2009 Category: Dentistry Authors: Shibazaki T, Yozgatian JH, Zeredo JL, Gonzales C, Hotokezaka H, Koga Y, Yoshida N Tags: Angle Orthod Source Type: journals

NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxibEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The consequences of the rofecoxib withdrawal on upper GI toxicity are largely unknown. We sought to estimate the effect of switching from selective Cox-2 inhibitors to non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) on the incidence of upper GI adverse events following the withdrawal of rofecoxib on 30 September 2004.We identified a cohort of 33 045 patients with arthritis and chronic use of any selective Cox-2 inhibitor during the 6 months before the withdrawal of rofecoxib in claims data from several US health plans. We calculated monthly rates of hospitalization for upper GI adverse events or upper GI end...
Source: Pharmacoepidemiology and Drug Safety - October 20, 2009 Category: Drugs & Pharmacology Authors: Sebastian Schneeweiss, Robert J. Glynn, Jerry Avorn, Muhammad Mamdani, Helen Mogun, Daniel H. Solomon Source Type: journals

Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: a systematic review and meta-analysisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Source: DARE Area: Evidence > Medication Safety CRD Summary: This review concluded that there is insufficient data to determine the impact of cyclooxygenase-2 inhibitors on the risk of inflammatory bowel disease exacerbations. The review was well conducted and the authors' cautious conclusion is justified given the evidence presented. [One study randomised participants to etoricoxib 60-120mg/d for three months, while the other trial used oral celecoxib 200mg or placebo twice a day for 14 days. ] CRD Commentary: This review addressed a clear question in terms of inclusion criteria, study design and participants. Releva...
Source: NeLM - Patient Safety - October 20, 2009 Category: Drugs & Pharmacology Source Type: organizations

Short-term Celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Short-term treatment with Celecoxib has an anti-carcinogenic effect, and resulted in less severe inflammation and inhibited the invasive degree of gastric cancer. PMID: 19842220 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - October 20, 2009 Category: Gastroenterology Authors: Kuo CH, Hu HM, Tsai PY, Wu IC, Yang SF, Chang LL, Wang JY, Jan CM, Wang WM, Wu DC Tags: World J Gastroenterol Source Type: journals

Proteomic analysis in NSAIDs-Treated primary cardiomyocytes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we tried to identify proteins responding to the cellular toxicity in NSAIDs-treated primarily cultured cardiomyocytes using 2-D proteomic analysis. We used seven different NSAIDs (celecoxib, rofecoxib, valdecoxib, diclofenac, naproxen, ibuprofen, meloxicam) possessing each different degree of cardiovascular risk. Overall protein spots were similar in all NSAIDs-treated cells although numbers of decreased proteins were about 2-fold higher in celecoxib or rofecoxib-treated cells than in cells incubated with other NSAIDs. Many stress-related proteins, cardiac muscle movement proteins and proteins involving in m...
Source: Journal of Proteomics - October 19, 2009 Category: Biochemistry Authors: Baek SM, Ahn JS, Noh HS, Park J, Kang SS, Kim DR Tags: J Proteomics Source Type: journals

Investigators At Massachusetts General Hospital Have Published New Data On Colon CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Although evidence suggests that aspirin and celecoxib may reduce the risk of colorectal cancer (CRC), these drugs can also cause harmful side effects. The aim of this study was to characterize patient preferences for celecoxib and aspirin, scientists in the United States report. (Source: Cancercompass News: Colorectal Cancer)
Source: Cancercompass News: Colorectal Cancer - October 17, 2009 Category: Cancer & Oncology Source Type: news

Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers [Genitourinary Cancer]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion Treatment with 4 to 6 weeks of celecoxib had no effect on intermediate biomarkers of prostate carcinogenesis, despite the achievement of measurable tissue levels. We caution against using celecoxib 400 mg twice daily as a preventive agent for prostate cancer in additional studies. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - October 16, 2009 Category: Cancer & Oncology Authors: Antonarakis, Heath, Walczak, Nelson, Fedor, De Marzo, Zahurak, Piantadosi, Dannenberg, Gurganus, Baker, Parnes, DeWeese, Partin, Carducci Tags: Clinical Trials, Chemoprevention studies, Surgery, Genitourinary Genitourinary Cancer Source Type: journals

Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in ratsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Celecoxib shows a proapoptotic effect on HSCs through Akt inactivation and shows antifibrogenic effects in BDL- and TAA-treated rats, suggesting celecoxib as a novel antifibrotic agent of hepatic fibrosis. (Source: Gut)
Source: Gut - October 15, 2009 Category: Gastroenterology Authors: Paik, Y-H, Kim, J K, Lee, J I, Kang, S H, Kim, D Y, An, S H, Lee, S J, Lee, D K, Han, K-H, Chon, C Y, Lee, S I, Lee, K S, Brenner, D A Tags: Cirrhosis, Pancreas and biliary tract Hepatology Source Type: journals

Inhibition of Azoxymethane-Induced Colorectal Cancer by CP-31398, a TP53 Modulator, Alone or in Combination with Low Doses of Celecoxib in Male F344 RatsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Tumor suppressor p53 plays a major role in colorectal cancer development. The present study explores the effects of p53-modulating agent CP-31398 alone and combined with celecoxib on azoxymethane-induced aberrant crypt foci (ACF) and colon adenocarcinomas in F344 rats. Maximum tolerated doses were 400 and 3,000 ppm for CP-31398 and celecoxib, respectively. ACF and tumor efficacy endpoints were carried out on azoxymethane-treated 7-week-old rats (48 per group) fed the control AIN-76A diet. Two weeks after carcinogen treatment, rats were fed the diets containing 0, 150, or 300 ppm CP-31398, 300 ppm celecoxib, or 150 ppm CP-3...
Source: Cancer Research - October 15, 2009 Category: Cancer & Oncology Authors: Rao, C. V., Steele, V. E., Swamy, M. V., Patlolla, J. M.R., Guruswamy, S., Kopelovich, L. Tags: Prevention Source Type: journals

Celecoxib: Multifocal fixed drug eruption: case reportEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Reactions)
Source: Reactions - October 12, 2009 Category: Drugs & Pharmacology Tags: Short communication Source Type: journals

Familial adenomatous polyposisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(FAP) is characterized by the development of hundreds to thousands of adenomas in the rectum and colon during the second decade of life. FAP has an incidence at birth of about 1/8,300, manifests equally in both sexes, and accounts for less than 1% colorectal cancer (CRC) cases. In the European Union, prevalence has been estimated at 1/11,300-37,600. Most patients are asymptomatic for years until the adenomas are large and numerous, and cause rectal bleeding or even anemia, or cancer develops. Generally, cancers start to develop a decade after the appearance of the polyps. Nonspecific symptoms may include constipation or d...
Source: Orphanet Journal of Rare Diseases - October 11, 2009 Category: Internal Medicine Authors: Elizabeth HalfDani BercovichPaul Rozen Source Type: journals

Chemopreventive effect of nonsteroidal anti-inflammatory drugs on 9,10-dimethylbenz[a]anthracene-induced lung carcinogenesis in mice.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, celecoxib, and etoricoxib were studied as chemopreventive agents in lung cancer in mice induced by 9,10-dimethylbenz[a]anthracene (DMBA). The animals were subjected to a single intratracheal instillation of DMBA by surgical intervention, while they were treated with oral NSAIDs daily at their following anti-inflammatory dose: aspirin 25 mg/kg, celicoxib 6 mg/kg, and etoricoxib 0.6 mg/kg body weight, respectively. The animals were sacrificed after 18 weeks of treatment. Results showed a significant incidence of pulmonary tumors, dysplastic changes in histopa...
Source: Oncology Research - October 9, 2009 Category: Cancer & Oncology Authors: Saini RK, Sanyal SN Tags: Oncol Res Source Type: journals

PC-407, a celecoxib derivative, inhibited the growth of colorectal tumor in vitro and in vivoEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study aimed to observe the growth-inhibitory effect of PC-407 (4-[5-naphthyl-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide), a celecoxib derivative synthesized in our lab, in human colorectal cancer cells and a colitis-associated colorectal cancer (CACC) model, and investigate the relative molecular mechanisms. SW-1116 (expressing a high level of cyclooxygenase-2 [COX-2]), HT-29 (expressing a moderate level of COX-2), and SW-480 (no expression of COX-2) cell lines were exposed to different concentrations of celecoxib (0[ndash]100 [mu]mol/L) or PC-407 (0[ndash]100 [mu]mol/L). Then, COX-2 levels were assessed ...
Source: Cancer Science - October 8, 2009 Category: Cancer & Oncology Authors: Yuhua Li, Yinbo Niu, Huanjie Wu, Bangle Zhang, Yang Sun, Haitao Huang, Qian Li, Lei Fan, Li Liu, Qibing Mei Source Type: journals

Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract Chronic inflammation is one of the main features of cancer cachexia. Experimental and clinical studies showed that cyclooxygenase-2 inhibitors, such as celecoxib, may be beneficial in counteracting major symptoms of this devastating syndrome. We carried out a prospective phase II clinical trial to test the safety and effectiveness of an intervention with the COX-2 inhibitor celecoxib (300 mg/day for 4 months) on key variables of cachexia (lean body mass, resting energy expenditure, serum levels of proinflammatory cytokines, and fatigue) in patients with advanced cancer at different sites. ...
Source: Journal of Molecular Medicine - October 3, 2009 Category: Molecular Biology Tags: Journal of Molecular Medicine Source Type: journals

The effects of celecoxib, a COX-2 selective inhibitor, on acute inflammation induced in irradiated ratsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract The potential value of selective and non-selective COX-2 inhibitors in preventing some of the biochemical changes induced by ionizing radiation was studied in rats exposed to carrageenan-induced paw edema and 6-day-old air pouch models. The animals were exposed to different exposure levels of γ-radiation, namely either to single doses of 2 and 7.5 Gy or a fractionated dose level of 7.5 Gy delivered as 0.5 Gy twice weekly for 7.5 weeks. The inflammatory response produced by carrageenan in irradiated rats was markedly higher than that induced in non-irradiated animals, and depende...
Source: Inflammopharmacology - October 1, 2009 Category: Drugs & Pharmacology Tags: Inflammopharmacology Source Type: journals

Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Progression of colon cancer is associated with the up-regulation of cyclooxygenase-2 (COX-2) and hydroxymethyl glutaryl CoA reductase (HMG-R). Clinical and preclinical evidence shows that a combination of COX-2 and HMG-R inhibitors provide additive/synergistic chemopreventive effects against colorectal cancer. However, the mechanism by which statins and NSAIDs inhibit cancer growth is not yet fully understood. We aimed to identify critical molecules and signal pathways modulated by a combination of lovastatin and celecoxib in the human HCT-116 colon cancer cell line. HCT-116 cells were exposed to 50 microM celecoxib, 2...
Source: International Journal of Oncology - October 1, 2009 Category: Cancer & Oncology Authors: Guruswamy S, Rao CV Tags: Int J Oncol Source Type: journals

Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of actionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Our findings confirm that BER suppresses the growth, migration and invasion in highly-metastatic human breast cancer cells by possibly inhibiting Akt and NF-kappaB signaling with their upstream target c-Met and downstream targets Bcl-2/Bax, osteopontin, VEGF, MMP-9 and MMP-2. BER has synergistic effects with anticancer agents trichostatin A, celecoxib, and carmofur on inhibiting the growth of MDA-MB-231 cells and reducing the ratio of Bcl-2/Bax and/or VEGF expressions in the cancer cells. These findings suggest that BER may have the wide therapeutic and/or adjuvant therapeutic application in the treatment of h...
Source: Molecular Cancer - September 30, 2009 Category: Cancer & Oncology Authors: Shan WangQian LiuYing ZhangKe LiuPengfei YuKun LiuJinling LuanHuiying DuanZhaoqiao LuFengfei WangErxi WuKazumi YagasakiGuoying Zhang Source Type: journals

Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We investigated the effects of several non-steroidal anti-inflammatory drugs on swelling related properties of mitochondria, with an emphasis on compounds that are marketed and utilized topically in the eye (nepafenac, ketorolac, diclofenac, bromfenac), and compared these to the effects of amfenac (a metabolite of nepafenac) and to celecoxib (active principle of Celebrex). With the exception of the last compound, none of the drugs promote swelling of normal mitochondria that are well energized by succinate oxidation. However, swelling is seen when the mitochondria are under an oxidative stress due to the presence of t-...
Source: Archives of Biochemistry and Biophysics - September 30, 2009 Category: Biochemistry Authors: Lal N, Kumar J, Erdahl WE, Pfeiffer DR, Gadd ME, Graff G, Yanni JM Tags: Arch Biochem Biophys Source Type: journals

[Inhibiting cyclooxygenase and 5-lipoxygenase activities is an anti-inflammatory mechanism of Huzhang Gout Granule.]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion:HZGG can reduce the releasing of inflammatory mediators, such as TXB2, PGI2 and LTB4, by inhibiting the activities of COX and 5-LOX. PMID: 19828108 [PubMed - in process] (Source: Zhong xi yi jie he xue bao : Journal of Chinese Integrative Medicine.)
Source: Zhong xi yi jie he xue bao : Journal of Chinese Integrative Medicine. - September 30, 2009 Category: Complementary Medicine Authors: Wang YF, Wu WJ, Zhang M, Zhou M, Li B Tags: Zhong Xi Yi Jie He Xue Bao Source Type: journals

Celecoxib reduces symptoms in men with difficult chronic pelvic pain syndrome (Category IIIA).Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We investigated the effectiveness of celecoxib in reducing symptoms in patients with difficult chronic pelvic pain syndrome (CPPS), NIH category IIIA. Sixty-four patients with category IIIA CPPS were randomized into two groups of 32 subjects each. One group was treated with celecoxib (200 mg daily) and the other with placebo. All patients underwent treatment for 6 weeks and were evaluated clinically before (baseline) and after 1, 2, 4, 6, and 8 weeks of treatment. The evaluation included the NIH Chronic Prostatitis Symptom Index (NIH-CPSI) and a subjective global assessment (SGA). Repeated measures analysis of variance...
Source: Braz J Med Biol Res - September 30, 2009 Category: Research Authors: Zhao WP, Zhang ZG, Li XD, Yu D, Rui XF, Li GH, Ding GQ Tags: Braz J Med Biol Res Source Type: journals

Evaluation of analgesic efficacy, gastrotoxicity and nephrotoxicity of fixed-dose combinations of nonselective, preferential and selective cyclooxgenase inhibitors with paracetamol in rats.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Nonsteroidal anti-inflammatory drugs (NSAIDs) are combined with paracetamol (PCM) with a view to enhance analgesic efficacy and reduce gastric toxicity. However, there are reports of enhanced nephrotoxicity with nonselective NSAID with PCM combinations. The present study investigated the analgesic efficacy, gastrotoxicity and nephrotoxicity of nonselective, preferential and selective cyclooxgenase inhibitors and their combination with PCM in rats. Graded doses of ibuprofen, meloxicam and celecoxib alone and their combination with fixed dose of PCM were administered to the rats by gavage for 14 days. The results showed ...
Source: Experimental and Toxicologic Pathology - September 29, 2009 Category: Pathology Authors: Kumar G, Hota D, Nahar Saikia U, Pandhi P Tags: Exp Toxicol Pathol Source Type: journals

Short-term celecoxib to regress long-term persistent gastric intestinal metaplasia after Helicobacter pylori eradicationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: Short-term celecoxib treatment can be safe and promising to regress long-term persistent IM after H. pylori eradication. (Source: Journal of Gastroenterology and Hepatology)
Source: Journal of Gastroenterology and Hepatology - September 26, 2009 Category: Gastroenterology Authors: Kuei-Hsiang Hung, Hsiao-Bai Yang, Hsiu-Chi Cheng, Jiunn-Jong Wu, Bor-Shyang Sheu Source Type: journals

Pfizer Urges Approval Of $89M Settlement Resolving Painkiller Consumer ClaimsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN FRANCISCO - Pfizer Inc. has ratified a motion by consolidated plaintiffs for approval of an $89 million settlement of consumer claims over Pfizer Inc.'s painkillers Bextra and Celebrex, saying in a Sept. 17 brief that plaintiffs would have difficulty overcoming courts' reluctance to accept aggregate proofs for class action claims (In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, MDL Docket No. 1699, No. M:05-CV-1699, N.D. Calif.; See August 2009, Page 4). Full story on lexis.com (Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News)
Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News - September 24, 2009 Category: Medical Law Source Type: info

Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg miceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Our results demonstrate the benefit that can be gained from using sPLA2 inhibitory peptide for RA treatment, and validate PIP-18 as a potential therapeutic in a clinically relevant animal model of human arthritis. (Source: Arthritis Research and Therapy)
Source: Arthritis Research and Therapy - September 17, 2009 Category: Rheumatology Authors: Maung-Maung ThwinEleni DouniPachiappan ArjunanGeorge KolliasPrem KumarPonnampalam Gopalakrishnakone Source Type: journals

Double blind randomized phase II study with radiation+5-fluorouracil±celecoxib for resectable rectal cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Addition of celecoxib to preoperative chemoradiation is feasible for patients with locally advanced rectal cancer. To study the individual effect of COX-2 inhibitors on pathological response phase III studies are required. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - September 11, 2009 Category: Radiology Authors: Annelies Debucquoy, Sarah Roels, Laurence Goethals, Louis Libbrecht, Eric Van Cutsem, Karel Geboes, Freddy Penninckx, André D’Hoore, William H. McBride, Karin Haustermans Tags: Original articles Source Type: journals

Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: Addition of celecoxib to preoperative chemoradiation is feasible for patients with locally advanced rectal cancer. To study the individual effect of COX-2 inhibitors on pathological response phase III studies are required. PMID: 19747744 [PubMed - as supplied by publisher] (Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology)
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - September 8, 2009 Category: Radiology Authors: Debucquoy A, Roels S, Goethals L, Libbrecht L, Cutsem EV, Geboes K, Penninckx F, D'Hoore A, McBride WH, Haustermans K Tags: Radiother Oncol Source Type: journals

CELEBREX (Celecoxib) Capsule [A-S Medication Solutions LLC]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Sep 8, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - September 8, 2009 Category: Drugs & Pharmacology Source Type: organizations

CELEBREX (Celecoxib) Capsule [A-S Medication Solutions LLC]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Updated Date: Sep 2, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - September 2, 2009 Category: Drugs & Pharmacology Source Type: organizations

Study on mechanism for amorphous drug stabilization using gelucire 50/13.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Methods of preparation and application of amorphous form are well established but it is equally important to note that devitrification of amorphous drugs has limited their applications. Present study was performed to investigate mechanism for amorphous drug stabilization using Gelucire in comparison with polyvinylpyrrolidone (PVP). Etoricoxib and celecoxib were taken as model drugs for this study, as etoricoxib has only proton accepting site for hydrogen bonding in comparison with celecoxib, which has both proton accepting and donating site. Solid dispersion of celecoxib with polyvinylpyrrolidone and Gelucire was prepa...
Source: Chemical and Pharmaceutical Bulletin - August 31, 2009 Category: Drugs & Pharmacology Authors: Shimpi SL, Mahadik KR, Paradkar AR Tags: Chem Pharm Bull (Tokyo) Source Type: journals

The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, CanadaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study showed a modest increased risk of AMI/CHD with various traditional NSAIDs and COX-2 inhibitors. Confidence intervals of estimated ORs included the null value for most comparisons. The study confirmed that the differentiation between traditional NSAIDs and COX-2 inhibitors is not a reliable tool for predicting cardiovascular risk associated with NSAIDs. Copyright © 2009 John Wiley & Sons, Ltd. (Source: Pharmacoepidemiology and Drug Safety)
Source: Pharmacoepidemiology and Drug Safety - August 28, 2009 Category: Drugs & Pharmacology Authors: Cristina Varas-Lorenzo, Jordi Castellsague, Mary Rose Stang, Susana Perez-Gutthann, Jaume Aguado, Luis Alberto García Rodriguez Source Type: journals

Plaintiff Attorneys Seek Final Approval Of Class For Pfizer Drug PurchasersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN FRANCISCO - Citing the small number of objectors and saying that an $89 million settlement of consumer claims over Pfizer Inc.'s painkillers Bextra and Celebrex was far less than what plaintiffs thought the claims were worth but far more than Pfizer acknowledged, plaintiffs' attorneys on Aug. 14 filed a motion for final approval of a class (In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, MDL Docket No. 1699, No. M:05-CV-1699, N.D. Calif.; See July 2009, Page 4). Full story on lexis.com (Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News)
Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News - August 28, 2009 Category: Medical Law Source Type: info

Settling Attorneys Say Objectors Lack Standing, Have The Right To SueEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN FRANCISCO - Two weeks before filing their motions for final approval of a refund class regarding Pfizer Inc.'s painkillers Bextra and Celebrex, multidistrict litigation attorneys representing the proposed settlement class filed a response saying objectors to the $89 million settlement lacked standing or had the right to opt out and sue (In Re: Bextra and Celebrex Marketing Sales Practices and Product Liability Litigation, MDL Docket No. 1699, No. M:05-CV-1699, N.D. Calif.; See July 2009, Page 4 and previous story in this issue). Full story on lexis.com (Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News)
Source: LexisNexis® Mealey's™ Arthritis Drugs Legal News - August 28, 2009 Category: Medical Law Source Type: info

Rho iso-alpha acids from hops inhibit the GSK-3/NF-kappaB pathway and reduce inflammatory markers associated with bone and cartilage degradationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: RIAA may have potential as an anti-inflammatory therapeutic. (Source: Journal of Inflammation)
Source: Journal of Inflammation - August 26, 2009 Category: Drugs & Pharmacology Authors: Veera Reddy KondaAnuradha DesaiGary DarlandJeffrey BlandMatthew Tripp Source Type: journals